Verona signs China deal for PhIII COPD drug; Teva continues legal battle with Eli Lilly, alleging new patent infringements on migraine drug

After a February Phase II win put Verona’s bad memories of a 2019 flop behind them, the company is now engaging in partnerships to ship out the experimental drug should it continue to produce positive results in Phase III.

Verona is teaming up with Nuance Pharma on a $219...

Click to view original post